Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBITDA: 2018-2025

Historic EBITDA for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -$59.2 million.

  • Bicycle Therapeutics' EBITDA fell 11.93% to -$59.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.9 million, marking a year-over-year decrease of 45.61%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.09% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported EBITDA of -$59.2 million as of Q3 2025, which was up 26.77% from -$80.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' EBITDA registered a high of -$14.4 million during Q3 2021, and its lowest value of -$80.9 million during Q2 2025.
  • Over the past 3 years, Bicycle Therapeutics' median EBITDA value was -$48.5 million (recorded in 2024), while the average stood at -$50.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 33.88% in 2024, then crashed by 139.41% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' EBITDA (Quarterly) stood at -$18.2 million in 2021, then crashed by 65.20% to -$30.1 million in 2022, then plummeted by 76.92% to -$53.3 million in 2023, then grew by 8.89% to -$48.5 million in 2024, then declined by 11.93% to -$59.2 million in 2025.
  • Its last three reported values are -$59.2 million in Q3 2025, -$80.9 million for Q2 2025, and -$62.3 million during Q1 2025.